Document:

Amended and Restated Executive Employment Agreement

 Exhibit 10.1 
 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 
 This Amended and Restated Executive Employment
Agreement (this “Agreement”) is made and entered into by and between The TriZetto Group, Inc. (the “Company”) and Jeffrey H. Margolis (“Executive”). Once signed by both of the parties, this
Agreement will be deemed effective as of January 1, 2006 (the “Effective Date”). This Agreement supersedes all previous agreements, promises, representations, understandings and negotiations between the parties, whether written
or oral, with respect to the subject matter hereof, except as expressly provided herein. 
 WHEREAS, the Company and Executive previously
entered into that certain Executive Employment Agreement, effective January 2, 2005 (the “Original Employment Agreement”), which sets forth the terms and conditions of Executive’s employment as Chief Executive Officer of
the Company; and 
 WHEREAS, the Company and Executive now desire to amend certain terms and conditions of the Original Employment Agreement
and restate the agreement in its entirety. 
 NOW, THEREFORE, in consideration of the mutual covenants herein contained, and other good and
valuable consideration, the parties hereto agree to amend and restate the Original Employment Agreement as of the date hereof as follows: 
 1. Employment. The Company hereby employs Executive as the Chief Executive Officer of the Company. Executive accepts such employment, reporting directly to the Board of Directors of the Company (“Board”). 

2. Term. The term of this Agreement and of Executive’s employment pursuant to this Agreement shall commence on the Effective Date
and end on the date that Executive’s employment may be terminated as provided in Section 6 below. 
 3. Place of
Performance. Executive shall be based at the Company’s office located in Orange County, California, but Executive from time-to time may be required to travel to other geographic locations in connection with the performance of his duties.

 4. Duties and Responsibilities. 
 4.1 Service with the Company. Executive shall work exclusively for the Company and shall have all the customary powers and duties associated with his position(s) as set forth in Section 1, above.
Executive shall devote his full business time and effort to the performance of his duties for the Company, which he shall perform faithfully and to the best of his ability. Executive shall be subject to the Company’s policies, procedures and
approval practices, as generally in effect from time-to-time. 
 4.2 No Conflicting Duties. During the term
hereof, Executive shall not serve as an officer, director, employee, consultant or advisor to any other competing business or as an officer, employee or consultant to any other business, unless such other service is approved by the Board. Executive
hereby confirms that he is under no contractual commitments inconsistent with his obligations set forth in this Agreement, and agrees that during the term of this 

 
Agreement he will not render or perform services, or enter into any contract to do so, for any other corporation, firm, entity or person which are
inconsistent with the provisions of this Agreement. The Company acknowledges and agrees that Executive may serve as a member of the Pfizer Health Solutions Advisory Board. 
 5. Compensation. 
 5.1 Annual Base Salary. As compensation for all services to be rendered by Executive under this Agreement, the Company shall pay to Executive a base annual salary of Five Hundred Forty-Six Thousand Twenty-One Dollars
($546,021) (“Annual Base Salary”), which salary shall be paid in conformity with the Company’s pay practices generally applicable to Company executives. Executive will be eligible for annual pay increases as determined by the Board.
If this Agreement is signed by the parties after the Effective Date, Executive’s Annual Base Salary shall be paid retroactively to the Effective Date. 
 5.2 Bonus. Executive will be eligible for annual bonus compensation in an amount to be determined by the Compensation Committee of the Board based on the Company’s achievement of financial
performance and other objectives, as well as Executive’s achievement of individual performance objectives, established by the Compensation Committee each year. If all Company and Executive’s individual performance objectives are met, it is
expected that the bonus paid, if any, will be equal to Executive’s Annual Base Salary for the year for which the bonus is paid. Any bonus awarded may be greater or less than Executive’s Annual Base Salary, depending on whether the
Company’s and Executive’s performance exceeds or falls short of the established objectives. 
 5.3 Stock
Options. In connection with his continuing employment with the Company, Executive was granted on February 9, 2005 a stock option to purchase 150,000 shares of the Company’s common stock at $8.48 per share (the “Option”). The
Option shall be subject to all the terms of The TriZetto Group, Inc. 1998 Long-Term Incentive Plan, under which it was granted, and the option agreement between Executive and the Company evidencing the Option. 
 5.4 [Reserved.] 
 5.5 Retention Incentive. As an incentive for Executive to remain an employee of the Company, the Company shall make three retention incentive payments (each, a “Retention Payment”) in the
amount of $44,227.78, less tax and other customary payroll withholdings and deductions, each to Executive. A Retention Payment shall be made on each of January 1, 2006, January 1, 2007, and January 1, 2008. Except as set forth in
Section 6.7(a), Executive must be an active employee on the payment date in order to be eligible to receive the applicable Retention Payment. 
 5.6 Annual Perquisites. Executive shall be entitled, at Company’s expense, to use for personal reasons the Company’s owned or leased aircraft for up to twenty-five (25) hours for each of
the calendar years ending December 31, 2006, 2007 and 2008. 
 5.7 Standard Benefits. During the term of
this Agreement, Executive shall be entitled to participate in all employee benefit plans and programs, including paid vacations, to the same extent generally available to Company executives, in accordance with the terms of 

 
those plans and programs. The Company shall have the right to terminate or change any such plan or program at any time. 
 5.8 Expense Reimbursement. Executive shall be entitled to receive prompt reimbursement for all reasonable and customary
travel and business expenses he incurs in connection with his employment, but must incur and account for those expenses in accordance with the policies and procedures established by the Company. 
 5.9 Indemnification. The Company shall indemnify Executive in his capacities as a director and officer of the Company to the
fullest extent allowed by law, as more fully described in the Indemnification Agreement dated April 17, 2003 or any successor agreement. 
 5.10 Sarbanes-Oxley Act Loan Prohibition. To the extent that any Company benefit, program, practice, arrangement or this Agreement would or might otherwise result in Executive’s receipt of an
illegal loan (“Loan”), the Company shall use reasonable efforts to provide Executive with a substitute for the Loan that is lawful and of at least equal value to Executive. If this cannot be done, or if doing so would be significantly more
expensive to the Company than making the Loan, the Company need not make the Loan to Executive or provide him a substitute for it. 
 6.
Termination. 
 6.1 Termination by the Company Without Cause. The Company may terminate Executive’s
employment pursuant to this Agreement without Cause (defined below) by giving ninety (90) days’ written notice to Executive. 
 6.2 Termination by the Company for Cause. The Company may terminate Executive’s employment and this Agreement for Cause. As used herein, “Cause” shall mean: 
 (a) The continued, unreasonable refusal or omission by Executive to perform any material duties required of him by this Agreement or as
reasonably requested by the Board of Directors of the Company if consistent with the terms of this Agreement; 
 (b) Any
material act or omission by Executive involving malfeasance or gross negligence in the performance of Executive’s duties to, or material deviation from any of the material policies or directives of, the Company, in a manner that materially
damages the Company; 
 (c) Conduct on the part of Executive which constitutes the breach of any statutory or common law duty
of loyalty to the Company, in a manner that materially damages the Company; or 
 (d) Any illegal act by Executive which
materially and adversely affects the business of the Company or any felony (other than traffic violations) committed by Executive, as evidenced by conviction thereof, provided that the Company may suspend the Executive with pay while any allegation
of such illegal or felonious act is investigated. 

 
Termination by the Company for cause shall be accomplished by written notice to Executive and shall be preceded by a written notice providing a reasonable
opportunity and timeframe (which timeframe shall not in any case exceed thirty (30) days) for Executive to correct his conduct. Any such termination shall be without prejudice to any other remedy to which the Company may be entitled either at
law, in equity, or under this Agreement. 
 6.3 Termination by Company for Death or Disability. Executive’s
employment pursuant to this Agreement shall be immediately terminated without notice by the Company (i) upon the death of the Executive or (ii) upon the Executive becoming totally disabled. For purposes of this Agreement, the term
“totally disabled” means an inability of Executive, due to a physical or mental illness, injury or impairment, to perform a substantial portion of his duties for a period of one hundred eighty (180) or more consecutive days, as
determined by the Company’s Board of Directors. 
 6.4 Termination by Executive Without Good Reason.
Executive may terminate Executive’s employment pursuant to this Agreement without any reason by giving ninety (90) days’ written notice to the Company. 
 6.5 Termination by Executive for Good Reason. Executive’s employment pursuant to this Agreement may be terminated by
Executive for “good reason” if Executive voluntarily terminates his employment as a result of any of the following: 
 (a) Without Executive’s prior written consent, a reduction in his then current Annual Base Salary, other than as part of across-the-board salary reductions affecting all similar executives of the Company; 
 (b) The taking of any action by the Company that would substantially diminish the aggregate value of the benefits provided the Executive
under the Executive’s medical, health, accident, disability insurance, life insurance, thrift and retirement plans in which he was participating on the date of this Agreement, other than any such reduction which is (i) required by law,
(ii) implemented in connection with a general concessionary arrangement affecting all employees or affecting the group of employees (senior management) of which the Executive is a member or (iii) generally applicable to all beneficiaries
of such plans; 
 (c) Without Executive’s prior written consent, a relocation of the Executive’s place of employment
outside of Orange County, California 
 (d) Removal of Executive from his position of Chief Executive Officer or from his
position on the Company’s Board of Directors; 
 (e) A reduction in duties and responsibilities which results in
Executive no longer having duties customary for a Chief Executive Officer; 
 (f) The Company materially breaches any
provision of this Agreement; or 
 (g) Any failure by any successor to the Company to assume the obligations under this
Agreement. 

 An event that is or would constitute Good Reason shall cease to be Good Reason if:
(i) Executive does not terminate his employment within 90 days after the event occurs; or (ii) before Executive terminates his employment, the Company reverses the action or cures the default that constitutes Good Reason within 10 business
days after Executive notifies the Company in writing that Good Reason exists. 
 6.6 Termination by Executive
Following Change in Control. If Executive’s employment terminates following a “Change in Control” (as that term is defined in Executive’s January 13, 2004 Change in Control Agreement or any successor agreement), and if
Executive is entitled to severance pay and benefits under that Change in Control agreement or a successor agreement, then Executive shall be entitled to receive, at his election, the payments or benefits under either this Agreement or the then
applicable Change in Control agreement. 
 6.7 Payments Upon Termination. 
 (a) Except as provided in Section 6.6 above, if during the term of this Agreement, the Company terminates Executive’s
employment for any reason other than Cause, death or, Disability or the Executive resigns for Good Reason, Executive shall receive the following compensation: 
 (i) the portion of his then current Annual Base Salary which has accrued through his date of termination; 
 (ii) any vested incentive payments, stock options and restricted stock to which Executive is entitled as of the date of termination
pursuant to this Agreement or any bonus or incentive compensation plan in which he is then participating, provided the payment thereof is not contingent or conditional on Executive’s continued employment with the Company or the satisfaction of
any other condition which has not been satisfied; provided, however, the Company shall give good faith consideration to paying Executive a pro-rata or full bonus for the bonus period most recently completed by Executive; 
 (iii) any payments for unused vacation and floating holidays, and reimbursement of expenses, which are due, accrued or payable as of the
date of Executive’s termination; and 
 (iv) if Executive signs a release of claims in a form acceptable to the Company,
the Company shall pay to Executive, in addition to the amounts set forth above, the following severance payments and benefits: 
 (A) salary continuation at Executive’s then current Annual Base Salary for a 24-month period, payable in accordance with the Company’s normal payroll procedures and policies as if Executive had remained employed with the Company,
starting on the first regular Company payday after the Company receives the signed release of claims and any revocation period has expired; 

 (B) medical and dental coverage continuation for a 24-month period following
Executive’s termination as if Executive had remained employed with the Company and to the same extent provided to Executive and his family immediately prior to the date of termination other than as part of across-the-board changes affecting
such coverage for similarly situated executives of the Company during this 24-month period; and 
 (C) payment in full of any
and all unpaid Retention Payments, payable no later than thirty (30) days after the date of Executive’s termination of employment. 
 (b) If Executive’s employment terminates as a result of him becoming totally disabled (as defined in Section 6.3) or death, then Executive or his heirs shall be entitled to payment of the amounts set
forth in Sections 6.6(a)(i), (ii) and (iii) above, plus a payment in an amount equal to one-half of Executive’s then current Annual Base Salary, payable no later than thirty (30) days after the date of Executive’s
termination of employment. 
 (c) If the Company terminates Executive’s employment for Cause or if Executive
voluntarily resigns for other than Good Reason, Executive shall only be entitled to the compensation set forth in Sections 6.6(a)(i), (ii) and (iii) above. Such amounts shall be paid in accordance with the Company’s normal payroll
procedures and policies. 
 (d) Notwithstanding anything herein to the contrary, to the extent that the Company in good
faith determines that any payment pursuant to this Section 6.7 provides for a “deferral of compensation” under Section 409A of the Internal Revenue Code, as amended (“Section 409A”), no amounts shall be payable to
Executive pursuant to this Section 6.7 prior to the earlier of (i) Executive’s death or “disability” (within the meaning of Section 409A(a)(2)(C)), or (ii) the date that is six months following the date of
Executive’s “separation from service” with the Company (within the meaning of Section 409A). 
 7.
Confidentiality. Executive acknowledges that he currently possesses or will acquire secret, confidential, or proprietary information or trade secrets concerning the operations, customers, future plans and business methods of the Company
(“Confidential Information”). 
 7.1 Promise Not to Disclose. Executive promises never to use or
disclose any Confidential Information before it has become generally known within the industry through no fault of his own. Executive agrees that this promise shall never expire. 
 7.2 Promise Not to Solicit. To prevent Executive from inevitably breaking his promises in this Section 7, he further
agrees that, while this Agreement is in effect and for 12 months after its termination: (i) as to any customer or supplier of the Company with whom he had dealings or about whom he acquired Confidential Information during his employment,
Executive will not solicit or attempt to solicit (or assist others to solicit) the customer or supplier to do business with any person or entity other than the Company; and (ii) will not solicit or attempt to solicit (or assist others to
solicit) for employment any person who is, or within the preceding 12 months was, an officer, manager or employee of the Company. 

 7.3 Promise Not to Engage in Certain Employment. Executive agrees that,
while this Agreement is in effect and for 12 months after its termination, he will not accept any employment or engage in any activity, without the written consent of the Board, if the loyal and complete fulfillment of his duties in such employment
or activity would inevitably require him to reveal or utilize Confidential Information, as reasonably determined by the Board. 
 7.4 Return of Property and Information. When Executive’s employment with the Company ends, he will promptly deliver to the Company, or, at its written instruction, will destroy, all documents, data, drawings, manuals,
letters, notes, reports, electronic mail, recordings, and copies of such materials, of or pertaining to the Company or any of its affiliated entities which are in his possession or control. 
 7.5 Intellectual Property. Intellectual property (including such things as all ideas, concepts, inventions, plans,
developments, software, data, configurations, materials (whether written or machine-readable), designs, drawings, illustrations and photographs that may be protectable, in whole or in part, under any patent, copyright, trademark, trade secret, or
other intellectual property law), developed, created, conceived, made or reduced to writing or practice during Executive’s employment with the Company, except intellectual property that has no relation to the Company or any of its customers
that he developed purely on his own time and at his own expense, shall be the sole and exclusive property of the Company, and Executive hereby assigns all of his rights, title and interest in any such intellectual property to the Company. In
addition, Executive acknowledges that the Intellectual Property and Technical Information Agreement between Executive and the Company, a copy of which attached to this Agreement as Schedule 1, remains in full force and effect, and to the extent any
of its terms conflict with any provision of this Section 7, the provision that provides the most protection shall prevail. 
 7.6 Enforcement of this Section. This Section 7 shall survive the termination of this Agreement for any reason. Executive acknowledges that (i) his services are of a special, unique and extraordinary character, and
it would be very difficult if not impossible to replace them, (ii) this Section’s terms are reasonable and necessary to protect the Company’s legitimate interest, (iii) this Section’s restrictions will not prevent Executive
from earning or seeking a livelihood, (iv) this Section’s restrictions shall apply wherever permitted by law, and (v) Executive’s violation of any of this Section’s terms would irreparably harm the Company. Accordingly,
Executive agrees that, if he violates any of the provisions of this Section 7, or the attached confidentiality agreement, the Company shall be entitled to, in addition to other remedies available to it, (a) terminate further severance
payments and benefits payable pursuant to Section 6.6(a) of this Agreement and (b) seek and obtain an injunction to be issued by any court of competent jurisdiction restraining him from committing or continuing any such violation, without
the need to prove the inadequacy of money damages or post any bond or for any other undertaking. 

 8. Notice. 
 8.1 To the Company. Executive will send all communications to the Company in writing, addressed as follows (or in any other
manner the Company notifies me to use), addressed as follows: 
  

			
	If Mailed:	  	 The TriZetto Group, Inc.
 Attn: James J. Sullivan,
Esq.
 567 San Nicolas Drive
 Newport Beach, California
92660

  

			
	If Faxed:	  	 The TriZetto Group, Inc.
 Attn: James J. Sullivan,
Esq.
 Fax: (949) 219-2197
 Tel.:
(949) 719-2215

 8.2 To Executive. All communications from the Company to Executive
relating to this Agreement must be sent to him in writing (or in any other manner he notifies the Company to use), addressed as follows: 
  

			
	If Mailed:	  	 Mr. Jeffrey H. Margolis
 c/o The TriZetto
Group, Inc.
 567 San Nicolas Drive
 Newport Beach, California
92660

  

			
	If Faxed:	  	 Mr. Jeffrey H. Margolis
 Fax:
(949) 219-2199
 Tel.: (949) 719-2205

 8.3 Time Notice Deemed Given. Notice shall be deemed to have been
given (i)when delivered; (ii) two business days after being mailed by United States certified or registered mail, return receipt requested, postage prepaid; or (iii) when faxed with confirmation of delivery. 
 9. Arbitration of Disputes. If any legally actionable dispute arises which cannot be resolved by mutual discussion between the Company and
Executive, each party hereto agrees to resolve that dispute by binding arbitration before an arbitrator experienced in employment law. Said arbitration will be conducted in accordance with the rules applicable to employment disputes of Judicial
Arbitration and Mediation Services or such other arbitration service as the Company and Executive agree upon, and the law of California. The Company will be responsible for paying any filing fee and the fees and costs of the arbitrator, unless
Executive initiates the claim, in which case he will contribute an amount equal to the filing fee for a claim initiated in a state court of general jurisdiction in California. The Company and Executive agree that this promise to arbitrate covers any
disputes that the Company may have against Executive, or that Executive may have against the Company and all of its affiliated entities and their directors, officers and employees, arising out of or relating to this Agreement, the employment
relationship or termination of employment, including any claims concerning the validity, interpretation, effect or violation of this Agreement; violation of any federal, state or local law; any tort; and any other aspect of Executive’s
compensation or employment. The Company and Executive further agree that arbitration as provided in this Section 9 shall be the exclusive and binding remedy for any such dispute and will be used instead of any court action, which is hereby
expressly waived, except for any request by either party hereto for temporary or preliminary injunctive relief pending arbitration in accordance with applicable law, or an 

 
administrative claim with an administrative agency. The Company and Executive also agree that any such arbitration shall be conducted in Orange County,
California, unless otherwise mutually agreed. 
 10. Golden Parachute Limitation. Executive agrees that the payments and
benefits under this Agreement, and all other contracts, arrangements or programs that apply to him, shall not, in the aggregate, exceed the maximum amount that may be paid to Executive without triggering golden parachute penalties under
Section 280G and related provisions of the Internal Revenue Code, as determined in good faith by the Company’s independent auditors. If any benefits must be cut back to avoid triggering such penalties, Executive’s benefits shall be
cut back in the priority order designated by the Company. If an amount in excess of the limits set forth in this Section 10 is paid to Executive, Executive agrees to repay the excess amount to the Company upon demand, with interest at the rate
provided for in Internal Revenue Code Section 124(b)(2)(B). The Company and Executive agree to cooperate with each other in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute
penalties with respect to payments or benefits Executive receives. 
 11. Amendment. No provisions of this Agreement may be
modified, waived, or discharged except by a written document signed by Executive and a duly authorized Company officer. Thus, for example, promotions, commendations, and/or bonuses shall not, by themselves, modify, amend, or extend this Agreement. A
waiver of any conditions or provisions of this Agreement in a given instance shall not be deemed a waiver of such conditions or provisions at any other time. 
 12. Interpretation and Exclusive Forum. The validity, interpretation, construction, and performance of this Agreement shall be governed by the laws of the State of California (excluding any that mandate
the use of another jurisdiction’s laws). Any arbitration (unless otherwise mutually agreed), litigation or similar proceeding with respect to such matters only may be brought within California, and all parties to this Agreement consent to
California’s jurisdiction. 
 13. Department of Homeland Security Verification Requirement. Executive agrees to timely
file all documents required by the Department of Homeland Security to verify his identity and lawful employment in the United States. Notwithstanding any other provision of this Agreement, if Executive fails to meet any such requirements promptly
after receiving a written request from the Company to do so, Executive agrees that his employment shall terminate immediately and that he shall not be entitled to any further compensation from the Company of any type. 
 14. Successors/Assignment. This Agreement shall be binding upon, and shall inure to the benefit of, Executive and his estate, but Executive
may not assign or pledge this Agreement or any rights arising under it, except to the extent permitted under the terms of the benefit plans in which he participates. The Company may not assign this Agreement to any affiliate or successor without
Executive’s prior written consent. 
 15. Withholding Taxes. The Company may withhold from any salary and benefits payable
under this Agreement all federal, state, city and other taxes or amounts as shall be 

 
determined by the Company to be required to be withheld pursuant to applicable laws, or governmental regulations or rulings. 
 16. Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any
other provision of this Agreement, which shall remain in full force and effect. 
 17. Counterparts. This Agreement may be
executed in one or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute the same instrument. 
 18. Entire Agreement. Except for Executive’s Change in Control Agreement, his Stock Option and Restricted Stock Agreements, his Indemnification Agreement and the Confidentiality Agreement signed on
December 25, 1997, all oral or written agreements or representations, express or implied, with respect to the subject matter of this Agreement are set forth in this Agreement. 
 [Signature page follows.] 

 EXECUTIVE ACKNOWLEDGES THAT ALL UNDERSTANDINGS AND AGREEMENTS BETWEEN THE COMPANY AND HIM RELATING TO THE SUBJECTS
COVERED IN THIS AGREEMENT ARE CONTAINED IN IT AND THAT HE HAS ENTERED INTO THIS AGREEMENT VOLUNTARILY AND NOT IN RELIANCE ON ANY PROMISES OR REPRESENTATIONS BY THE COMPANY OTHER THAN THOSE CONTAINED IN THIS AGREEMENT. 
 EXECUTIVE FURTHER ACKNOWLEDGES THAT HE HAS CAREFULLY READ THIS AGREEMENT, THAT HE UNDERSTANDS ALL OF IT, AND THAT HE HAS BEEN GIVEN THE OPPORTUNITY TO DISCUSS THIS
AGREEMENT WITH HIS PRIVATE LEGAL COUNSEL AND HAS AVAILED HIMSELF OF THAT OPPORTUNITY TO THE EXTENT HE WISHED TO DO SO. EXECUTIVE UNDERSTANDS THAT BY SIGNING THIS AGREEMENT HE IS GIVING UP HIS RIGHT TO A JURY TRIAL. 
  

									
	Date: August 14, 2006	 		 	 “Company”
 THE TRIZETTO
GROUP, INC.

					
		 		 		 	By:	 	/s/ James C. Malone
		 		 		 		 	 James C. Malone
 Executive Vice President and Chief
Financial Officer

  

					
	Date: August 14, 2006	 		 	“Executive”
			
	 	 		 	/s/ Jeffrey H. Margolis
		 		 	Jeffrey H. MargolisSettlement and License Agreement and Mutual General Release

 Exhibit 10.3 
 SETTLEMENT AND LICENSE AGREEMENT 
 AND 
 MUTUAL GENERAL RELEASE 
 This Settlement and License Agreement and Mutual
General Release (the “Agreement”) is made and entered into by and between MCKESSON INFORMATION SOLUTIONS LLC (“McKesson”), a Delaware Corporation with its principal offices at 5995 Windward Parkway, Alpharetta, Georgia 30005, and
THE TRIZETTO GROUP, INC. (“TriZetto”), a Delaware corporation with its principal offices at 567 San Nicolas Drive, Suite 360, Newport Beach, California 92660. The Agreement is effective as of the date last executed by the parties as set
forth next to its signature below, whichever date is later (the “Effective Date”). Where appropriate, McKesson and TriZetto are collectively referred to herein as the “Parties.” 
 RECITALS 
 A. On
October 12, 1993, U.S. Patent No. 5,253,164 (the “‘164 patent”), titled “System and Method For Detecting Fraudulent Medical Claims Via Examination Of Service Codes,” was issued by the United States Patent and
Trademark Office, naming Don C. Holloway, Robert D. Hertenstein, George A. Goldberg, and Kelli A. Dugan as inventors. The ‘164 patent has an effective filing date of September 30, 1988, and it will expire on October 12, 2010. The
‘164 patent was assigned to Health Payment Review, Inc. (“HPR”) by the named inventors. 
 B. HPR was acquired by
HBO & Company (“HBOC”) effective December 1997. HBOC previously acquired Gabrieli Medical Information Systems, Inc. (“GMIS”) effective December, 1996. McKesson Corporation completed a merger with HBOC in January 1999.
McKesson is a subsidiary of McKesson Corporation and is the current assignee of the ‘164 

 
patent. References herein to McKesson shall include its predecessors in interest, HPR, HBOC and GMIS. 
 C. TriZetto acquired Erisco Managed Care Technologies, Inc. (“Erisco”) effective October 2000. TriZetto acquired Resource Information
Management Systems, Inc. (“RIMS”) effective December 2000. TriZetto makes and sells in the United States software products under the names ClaimFacts, Facets, and QicLink. References herein to TriZetto shall include its predecessors in
interest, Erisco and RIMS. 
 D. On September 13, 2004, McKesson filed a complaint against TriZetto in the District Court for the
District of Delaware captioned McKesson Information Solutions LLC v. The TriZetto Group, Inc., Civil Action No. 04-1258-SLR (the “Action”), alleging one cause of action for infringement of the ‘164 patent (the
“Complaint”). 
 E. On November 1, 2004, TriZetto answered the Complaint, denying the material allegations therein, and filed
a counterclaim for declaratory judgment of non-infringement, invalidity, and unenforceability of the ‘164 patent (the “Answer and Counterclaim”). The Complaint, Answer and Counterclaim and all submissions made by the Parties in the
Action are hereinafter referred to as the “Pleadings and Filings.” 
 F. The Parties desire to settle and resolve the Action and
enter into a settlement agreement which provides for dismissal of the Action. This Settlement is made to avoid the uncertainty, time, and expense associated with further litigation and appeals, and neither party makes any admissions whatsoever,
including without limitation any admissions or acknowledgements of liability, infringement, or validity of the ‘164 Patent. 
  

 2 

 G. In connection with the settlement of the Action, TriZetto desires to obtain, and McKesson is willing
to grant, a non-exclusive license to the ‘164 Patent, subject to all of the terms and conditions of this Agreement. 
 NOW THEREFORE, it
is understood and agreed by the Parties that in full, sufficient, and complete consideration of the mutual promises and covenants contained herein, the Parties hereby agree as follows: 
 AGREEMENT 
  

	 	1.	Definitions 

 For purposes of
this Agreement, all terms not otherwise defined are defined below, which definitions are expressly incorporated herein by this reference. 
 1.1 Clinical Editing Database. A database containing information on medical procedure codes, including relationships among two or more medical procedure codes defining whether selected ones of the medical
procedure codes are appropriate for payment when input with other selected ones of the medical procedure codes. 
 1.2
Clinical Editing Product. Software that includes and/or uses a Clinical Editing Database in connection with the processing of medical claims for payment. For purposes of this Agreement, and without limiting the foregoing, software that does
not include or use a Clinical Editing Database shall not be considered a Clinical Editing Product even if such software includes or performs code validation and/or duplicate code functionality. 
 1.3 Covered Products. The terms “Covered Facets Product,” “Covered QicLink Product,” and “Covered
ClaimFacts Product” (collectively, “Covered Products”) refer to any version of Facets, QicLink, or ClaimFacts (including successor products thereto), respectively, that contains a TriZetto Clinical Editing Product. 
  

 3 

 1.4 Enhancements. Modifications, revisions, additions, or supplements to a
TriZetto Clinical Editing Product (including, without limitation, its Clinical Editing Database) which enables the TriZetto Clinical Editing Product to provide or perform material services or functions it could not previously perform, or materially
improves the manner in which the TriZetto Clinical Editing Product performs existing functions. Enhancements shall not include updates to a TriZetto Clinical Editing Product that are made to stay current with industry coding changes (e.g., changes
to the CPT and ICD codes and/or rules), regulatory requirements, as well as other minor upgrades, minor improvements, and/or fixes to such Product. Notwithstanding the foregoing, the term Enhancements shall include any modification, revision,
addition or supplementation to a TriZetto Clinical Editing Product that results in the addition, incorporation, inclusion or use of any part of or functionality from a non-TriZetto Clinical Editing Product, including, without limitation, its source
code and/or some or all of the contents of its Clinical Editing Database. 
 1.5 Existing TriZetto Customer. This
definition includes two categories of customers: (1) any and all ClaimFacts, QicLink or Facets customers that have acquired rights as of the Effective Date to use ClaimFacts, QicLink, or Facets on a licensed and/or hosted basis; and
(2) any prospective customer of ClaimFacts, QicLink, or Facets that is included in a TriZetto sales cycle as of the Effective Date and which customer enters into a license and/or hosting agreement for ClaimFacts, QicLink, or Facets with
TriZetto on or prior to October 31, 2006. The customers in the first category are identified on Exhibit 1 hereto, and prospective customers included in a TriZetto sales cycle as of the Effective Date are identified on Exhibit 2
hereto. Exhibit 2 of this Agreement shall be replaced by a final list of customers in the second category that will be provided by TriZetto to McKesson no later than November 30, 2006. When 

  

 4 

 
referring to Existing TriZetto Customers of a particular product, such customers shall be referred to as Existing ClaimFacts Customers (in the case of
ClaimFacts), Existing Facets Customers (in the case of Facets), and Existing QicLink Customers (in the case of QicLink). 
 1.6 Facets-ClaimCheck Interface. The software that enables transmission of data between Facets and ClaimCheck (including ClaimReview). 
 1.7 McKesson Products. McKesson’s products known individually as ClaimCheck, ClaimReview, Clear Claim Connection, and ClaimsXten; provided, however, that ClaimsXten shall be included in the definition of
McKesson Products only in the event that an interface is developed by TriZetto as set forth in Section 5.2 of this Agreement. 
 1.8 Net Licensing Revenue. The money actually received by TriZetto for licensing (including on a hosted basis) a Covered QicLink Product or Covered Facets Product. Net Licensing Revenue includes only base QicLink or Facets license
fees actually paid by customers to TriZetto; i.e., Net Licensing Revenue shall include fees paid by customers to use and access the Covered Products (including access provided on a hosted basis), but not fees paid for other products and services
provided by TriZetto, including the portion of hosted services related to the provision of servers, equipment and other infrastructure. For purposes of clarification only, and not as a limitation, Net Licensing Revenue does not include fees or
expenses paid by customers for (i) other products offered by TriZetto, such as Sybase, NetworX, Workflow, and/or Care Advance Enterprise, or (ii) any services provided by TriZetto, such as hosting, support, consulting, and/or maintenance
services. For purposes of this Agreement, fees or expenses for hosting services provided by TriZetto excludes fees for licensing a Covered QicLink Product or Covered Facets Product on a hosted basis. 
  

 5 

 1.9 New Facets or ClaimFacts Customer. Any customer that is sold Facets or
ClaimFacts on a licensed and/or hosted basis during the Term and that is not an Existing Facets or ClaimFacts Customer or a Small Facets Customer. 
 1.10 New QicLink Customer. Any customer that is sold QicLink on a licensed and/or hosted basis during the Term and that is not an Existing QicLink Customer. 
 1.11 Term. The period commencing on the Effective Date and ending on October 12, 2010, unless the Agreement is terminated
earlier as permitted herein. This Agreement and all the rights and obligations set forth herein shall remain in effect notwithstanding that the ‘164 Patent may be held invalid and/or unenforceable in any other proceeding at a later date.

 1.12 Small Facets Customer. Any customer other than an Existing Facets Customer that, at the time of first
contracting with TriZetto, contracts to use Facets for only those of its affiliates, divisions and/or product lines with aggregate membership at such time of 100,000 active medical lives or less. If a customer subsequently modifies its initial
contract with TriZetto to allow for the use of Facets by additional affiliates, divisions and/or product lines, and the total membership of all such contracted affiliates, divisions and/or product lines exceeds 100,000 active medical lives at the
time of such modification, then none of the additional affiliates, divisions and/or product lines will be deemed to be a Small Facets Customer. 
 1.13 TriZetto Clinical Editing Product. A Clinical Editing Product developed by TriZetto, including, without limitation, ClinicaLogic (also sometimes referred to as, among other things, Clinical Editing,
Clinical Editor, and Clinical Edits). In the event TriZetto assigns or otherwise transfers this Agreement pursuant to Section 2.3(b) below, the term TriZetto Clinical Editing Product shall be limited to those TriZetto Clinical Editing Products
that existed 

  

 6 

 
prior to said assignment or transfer and shall not include any Clinical Editing Product owned by the assignee or transferee at the time of the assignment or
transfer or thereafter acquired or developed by said assignee or transferee. 
 1.14 ‘164 Patent. The ‘164
patent as well as all foreign counterparts, continuations, divisionals, reexams, and reissues thereof, if any. 
  

	 	2.	License Grant and Royalties 

 2.1 In exchange for the promises, covenants, and obligations set forth in this Agreement, TriZetto will pay McKesson a one-time royalty fee of fifteen million dollars ($15,000,000) (the “Upfront Royalty Fee”) to license the
‘164 Patent with respect to all TriZetto’s sales of ClaimFacts, Facets, and QicLink as permitted herein. The Upfront Royalty Fee shall be payable in two equal installments of $7,500,000 each, the first to be paid by September 30,
2006, and the second to be paid by September 30, 2007. 
 2.2 (a) McKesson hereby grants to TriZetto a
non-exclusive, non-transferable (except as provided herein), non-assignable (except as provided herein), and non-sublicensable license under the ‘164 Patent to make, have made, use, import, license, sell, lease, offer for sale, support, host,
maintain, and otherwise transfer within the United States and its territories (i) Covered ClaimFacts, Facets, and QicLink Products to or for Existing ClaimFacts, Facets, and QicLink Customers; (ii) Covered Facets Products to or for Small
Facets Customers; and (iii) Covered QicLink Products to or for New QicLink Customers; and 
 2.2 (b) McKesson hereby
grants a non-transferable (except as provided herein), non-assignable (except as provided herein), non-sublicensable and non-exclusive license under the ‘164 Patent within the United States and its territories to (i) Existing ClaimFacts,
Facets, and QicLink Customers to use Covered ClaimFacts, Facets, and QicLink Products; (ii)

  

 7 

 
Small Facets Customers to use Covered Facets Products; and (iii) New QicLink Customers to use Covered QicLink Products. 
 2.3 (a) The licenses set forth in Section 2.2(b) are non-assignable and non-transferable by TriZetto’s customers except
(i) with the prior written consent of McKesson which shall not be unreasonably withheld; (ii) in connection with the sale of all or substantially all of the stock or assets of a TriZetto Customer; or (iii) to a purchaser of all or
substantially all of the assets of the business relating to the license. By way of clarification, and not as a limitation, if an Existing TriZetto Customer sells the business that is utilizing a licensed TriZetto product for the processing of
medical claims for payments, such license shall be transferable and/or assignable to the purchaser of such Customer’s business. 
 2.3 (b) This Agreement is assignable and transferable by TriZetto (i) with the prior written consent of McKesson which shall not be unreasonably withheld; (ii) in connection with the sale of all or substantially all of the
stock or assets of TriZetto; or (iii) to a purchaser of all or substantially all of the assets of the TriZetto business relating to the Agreement. Notwithstanding the foregoing, this Agreement is not assignable and not transferable by TriZetto
to Ingenix, Inc. or iHealth Technologies, Inc., including their respective parents, subsidiaries, affiliates, successors and assigns (each, a “Restricted Transferee”), under any circumstances. In the event a Restricted Transferee acquires
substantially all of the stock or assets of TriZetto, and TriZetto desires to transfer this Agreement to such Restricted Transferee, McKesson shall have the option to consent to or reject such a transfer. If McKesson elects to reject the transfer,
this Agreement shall terminate and the provisions of Section 9 shall apply. If TriZetto desires to transfer this Agreement to such Restricted Transferee, TriZetto shall give McKesson written notice of its intent to transfer the Agreement.
Within 15 calendar days of its 

  

 8 

 
receipt of such notice, McKesson shall give TriZetto written notice of its election to consent to or reject the transfer. If McKesson does not respond within
said 15 days, TriZetto will give McKesson a second written notice. If McKesson does not provide TriZetto with its written election within 15 calendar days after the second notice, it will be deemed to have rejected the transfer and this Agreement
will terminate and the provisions of Section 9 shall apply. In connection with an assignment or other transfer of this Agreement by TriZetto under this Section 2.3(b), the assignee or transferee must expressly assume in writing all of
TriZetto’s obligations hereunder. This Agreement is assignable and transferable by McKesson (i) with TriZetto’s prior written consent, which shall not be unreasonably withheld; (ii) in connection with the sale of all or
substantially all of the stock or assets of McKesson; (iii) to a purchaser of all or substantially all of the assets of the McKesson business relating to this Agreement; or (iv) to any direct or indirect wholly owned subsidiary of McKesson
Corporation including McKesson Health Solutions, LLC. 
 2.4 As of the Effective Date, TriZetto (i) shall not sell or
offer for sale on a licensed and/or hosted basis any TriZetto Clinical Editing Product (whether alone or with another product) to any New ClaimFacts or New Facets Customer within the United States of America and its territories; and (ii) shall
remove any TriZetto Clinical Editing Product from any version of ClaimFacts or Facets (or any product that replaces Facets) that is sold on a licensed and/or hosted basis to any such New Facets or New ClaimFacts Customer within the United States of
America or its territories. Such removal shall be performed prior to the delivery of ClaimFacts or Facets to the New Facets or New ClaimFacts Customer. This Section 2.4 shall not preclude TriZetto from selling or licensing Facets with a
TriZetto Clinical Editing Product to an Existing ClaimFacts Customer if that Customer was licensed to use ClinicaLogic as of the date 

  

 9 

 
of this Agreement, and the royalty fee in Section 2.5 shall not apply to any such sales or licenses. Nothing in this Agreement shall preclude Existing
ClaimFacts or QicLink Customers who convert to Facets from electing to license ClaimCheck or ClaimsXten. 
 2.5 In addition to
the Upfront Royalty Fee, in the event that TriZetto (whether on its own or through its vendor, distributor, partner, subsidiary, agent, or other representative) transfers, sells, hosts, or licenses a Covered Facets Product to a Small Facets Customer
or a Covered QicLink Product to a New QicLink Customer, TriZetto will pay McKesson a royalty of five percent (5%) of the Net Licensing Revenue from such Small Facets Customer or New QicLink Customer. Such royalties will be payable within
forty-five (45) days after the close of the calendar quarter in which such Net Licensing Revenue is actually received by TriZetto. 
 2.6 During the Term, TriZetto agrees that it will not make any Enhancements to any TriZetto Clinical Editing Product. 
 2.7 Notwithstanding any other provision of this Agreement, nothing in this Agreement shall preclude TriZetto from making, having made, using, importing, licensing, selling, leasing, offering for sale, supporting,
hosting, maintaining, and otherwise transferring any version of Facets that does not include a Clinical Editing Product. In the event TriZetto does sell versions of Facets described in this Section 2.7, McKesson shall not be entitled to any
portion of the resulting revenue received from such customer(s). 
 2.8 All royalty payments hereunder shall be noncreditable
and nonrefundable, except in connection with an overpayment of such royalties. All royalty payments hereunder shall be in United States dollars in immediately available funds and shall be made by wire transfer to such bank account as may be
designated from time to time by McKesson. 
  

 10 

 2.9 If TriZetto fails to timely make any payment due to McKesson under this Agreement,
then interest shall accrue on a daily basis at a compound annual rate of ten percent (10%) or at the maximum rate permitted by applicable law, whichever is lower, thirty (30) days from the time the payment was due until the time the
payment is made. 
 2.10 Other than the licenses granted in this Section 2 of this Agreement, nothing in this Agreement
shall grant to TriZetto, its customers, or any other person, by implication, estoppel, or otherwise, any right or license to the ‘164 Patent in general, or any other intellectual property rights owned by McKesson. 
 2.11 TriZetto shall mark any new versions of the Covered Products with the word “Patent” or the abbreviation “Pat.,”
and the full number of the ‘164 patent (or, if marking the Covered Products cannot be done, by affixing to the Covered Products or their packaging a label with such information). All such versions of Covered Products shall be marked permanently
and legibly in the manner as reasonably practical and directed by McKesson. Within sixty (60) days of the Effective Date or the release of any new version of a Covered Product (whichever is sooner), TriZetto shall certify to McKesson in writing
that it has complied with this Section 2.11. 
 2.12 The Parties grant each other limited permission to use the
trademarks of the other Party solely to identify themselves as working with the other Party pursuant to this Agreement and to advertise and promote the McKesson Products, the Facets-ClaimCheck Interface, and (if applicable) the Facets-ClaimsXten
Interface to New and Existing Facets Customers. Each Party shall provide to the other Party a sample of any proposed use of the other Party’s trademarks pursuant to this Section prior to such use. If the other Party objects to such 

  

 11 

 
use, said Party must provide its objection and/or any proposed revisions to the Party proposing such use within fifteen (15) business days of service.

 2.13 THE LICENSES GRANTED HEREUNDER BY MCKESSON ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. EXCEPT AS SET FORTH IN THIS AGREEMENT, MCKESSON MAKES NO WARRANTY THAT TRIZETTO’S ACTIVITIES UNDER SAID LICENSES WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. MCKESSON
WILL NOT BE LIABLE FOR ANY SUCH INFRINGEMENT, OR ALLEGATION THEREOF. 
 2.14 EXCEPT AS SET FORTH IN THIS AGREEMENT, NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY, ITS CUSTOMERS, THE USERS OF ANY PRODUCT, OR ANY THIRD PARTIES FOR INDIRECT, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING, WITHOUT LIMITATION, ANY DAMAGE OR INJURY TO BUSINESS EARNINGS, PROFITS, OR
GOODWILL SUFFERED BY ANY PERSON ARISING FROM ANY BREACH OF THIS AGREEMENT OR WARRANTY THEREIN, ANY EXERCISE OF RIGHTS UNDER THIS AGREEMENT, OR ANY USE OF THE ‘164 PATENT OR ANY PRODUCT, IN EACH CASE EVEN IF SUCH PARTY IS ADVISED OF THE
POSSIBILITY OF SUCH DAMAGE OR INJURY. 
 2.15 TriZetto shall keep and maintain proper books and records as are required
accurately to determine the royalties payable to McKesson for two (2) years following the calendar quarter on which such royalties were paid or reported. Once a year, and upon a two-week written notice to TriZetto, McKesson may have an
independent third-party accountant, at McKesson’s expense, examine TriZetto’s books and records solely for the purpose of verifying 

  

 12 

 
the accuracy of royalties paid or reported by TriZetto. TriZetto shall assist the accountant in conducting such examination, without charge, and shall make
such documents available for inspection and copying, shall make TriZetto’s personnel available for interviews, and shall make TriZetto’s facilities available for inspection as may be reasonably necessary to allow the accountant to perform
the examination. If such examination reveals an underpayment by TriZetto, then TriZetto shall promptly make up such underpayment with interest pursuant to Section 2.8, and, if the underpayment exceeds ten percent (10%) of the amount
actually owed to McKesson under this Agreement during the period under examination, TriZetto shall reimburse McKesson for the actual cost of the examination. If such examination reveals an overpayment by TriZetto, then McKesson shall promptly refund
such overpayment without interest to TriZetto. 
 2.16 As part of each royalty payment made pursuant to Section 2.5,
TriZetto shall provide McKesson with a quarterly report identifying each product sold and the date of such sale. If any Net Licensing Revenue has been received by TriZetto for such sale, the report shall also identify the amount of such Revenue and
the date on which TriZetto received such Revenue. 
 2.17 Each Party receiving monies under this Agreement shall be solely
responsible for all withholding, sales, use, excise and property taxes, and all duties, levies and assessments (other than those based on the net income of the other paying Party) imposed with respect to such receiving Party’s receipt of
payments pursuant to this Agreement. 
  

	 	3.	Promotion of McKesson Products to TriZetto Customers 

 3.1 During the Term, TriZetto shall use reasonable good faith efforts to promote the use and implementation of McKesson Products to Existing Facets Customers and New Facets Customers on a non-exclusive basis in
accordance with Section 4 below. TriZetto 

  

 13 

 
will have no obligation to promote McKesson Products to ClaimFacts, QicLink or Small Facets Customers, unless such customers become Facets Customers.

 3.2 Provided that TriZetto is in compliance with its obligations set forth in this Agreement, including Sections 2.4, 3, 4
and 5, TriZetto bears no responsibility and incurs no liability for the decision made by any TriZetto customer to purchase or license a Clinical Editing Product from any third-party source. 
 3.3 TriZetto will not be entitled to share any revenue derived by McKesson relating to McKesson Products, including revenue derived as a
result of any sale or license of McKesson Products to any TriZetto customers, provided however, that TriZetto may charge reasonable, standard and customary fees to license and support the Facets-ClaimCheck Interface and (if applicable) the
Facets-ClaimsXten Interface for any Existing TriZetto Customer that acquires ClaimCheck or ClaimsXten. 
 3.4 McKesson agrees
that all fees and service charges charged to any Facets customer for the sale or license of a McKesson Product will be consistent with the fees and services generally charged and provided to similar non-TriZetto customers. 
 3.5 McKesson will be solely responsible for all selling, contracting and collection efforts associated with the sales of McKesson Products
to Facets customers. 
 3.6 As of the Effective Date, McKesson will become a TriZetto “Preferred Alliance Partner.”
As a “Preferred Alliance Partner,” McKesson shall be invited and provided a bona fide opportunity to exhibit McKesson Products at TriZetto’s annual payor conference at TriZetto’s standard exhibition cost, which may vary
based upon level of customer exposure and publicity sought by McKesson. Such costs shall be payable by McKesson in accordance with TriZetto’s standard exhibitor payment policy. 
  

 14 

 3.7 This Agreement shall not affect the four current TriZetto customers that use
ClaimCheck as of the Effective Date; the Parties shall continue their current relationship and practices with regard to those four customers. All interfaces developed under this Agreement will, however, be made available to those customers.

  

	 	4.	TriZetto Promotional Efforts 

 4.1 When referring to clinical editing in its promotional materials, TriZetto will refer to McKesson Products for which interface(s) are created in accordance with Section 5 as a preferred clinical editing solution for prospective
customers seeking to use Facets for over 100,000 medical lives. 
 4.2 When responding to any RFP (request for proposal)
submitted by a prospective customer (other than a prospective Small Facets Customer) seeking to use Facets, TriZetto will refer to McKesson Products for which interface(s) are created in accordance with Section 5 as a preferred clinical editing
solution. 
 4.3 Nothing in this Agreement, including without limitation Section 2.4 above, shall preclude TriZetto from
creating interfaces for and/or promoting Clinical Editing Products from vendors other than McKesson, and McKesson is expected to compete with such other vendors on price and functionality. Notwithstanding the foregoing, nothing in this Agreement
shall be construed as (i) an admission regarding whether any Clinical Editing Product from any third party does not infringe or is licensed under the ‘164 Patent; (ii) a waiver of any right that McKesson may have under the ‘164
Patent with respect to any Clinical Editing Product from any third party; or (iii) granting, by implication, estoppel, or otherwise, any right or license under the ‘164 Patent to any person with respect to any Clinical Editing Product from
any third 

  

 15 

 
party. By way of this Agreement, neither McKesson nor TriZetto makes any admission as to whether any third party does or does not have a license to the
‘164 Patent. 
 4.4 On an annual basis, TriZetto will provide a list of all current Facets, ClaimFacts and QicLink
customers that are not included on either Exhibits 1 or 2 hereto, provided, however, that said lists will be given only to McKesson personnel agreed upon by the Parties and subject to the confidentiality provisions of Section 8.2.

 4.5 TriZetto will facilitate and jointly participate in up to two webinars or other marketing events per year for
TriZetto’s customer base that are sponsored and financed by McKesson. 
 4.6 TriZetto will participate in an annual
McKesson sales and marketing planning meeting. Members of TriZetto’s Facets sales team will meet with McKesson to discuss sales, marketing, education and training to maintain and support channel focus and lead generation efforts. 
 4.7 Each Party will designate one executive sponsor and three representatives to serve as primary points of contact, one for the overall
relationship, one for sales and marketing, and one for services, support and implementations. The role of the designated representatives will be to facilitate communications between the Parties on all matters that may arise under the Agreement.

 4.8 The executive sponsors and designated representatives from both Parties will participate in business review meetings on
a quarterly basis during the first twelve months following the Effective Date of this Agreement, and on a semi-annual basis thereafter. 
 4.9 TriZetto shall have no promotional obligations with respect to McKesson Products except as expressly set forth in Sections 3 and 4 of this Agreement. 
  

 16 

	 	5.	Software Interfaces 

 5.1 At
TriZetto’s expense, TriZetto will update the Facets-ClaimCheck Interface up to current general availability release versions of both Facets and ClaimCheck, including the current general release version of the clinical content in ClaimCheck,
existing as of the Effective Date of this Agreement. The Parties shall fully cooperate with each other in modifying the existing interface, including, but not limited to, providing access to knowledgeable personnel, confidential information and
source code. Nothing in this Section 5.1, however, shall be construed as shifting in any way the responsibility to update the Facets-ClaimCheck Interface up to current general release versions of both Facets and ClaimCheck, which responsibility
shall remain with TriZetto provided the Parties both cooperate and work together in connection with such update. McKesson will not be reimbursed for its costs or expenses, including but not limited to the time spent by its personnel on this project.
Upon the Effective Date of this Agreement, in addition to any representatives designated under Section 4.7 of this Agreement, each Party shall designate one or more representatives whose role will be to facilitate communications between the
Parties on all matters that may arise regarding the interfaces described in Sections 5.1 and (if applicable) 5.2 of the Agreement. TriZetto will not customize any of the interfaces described in Sections 5.1 and (if applicable) 5.2 for any customer
without the express written consent of McKesson. 
 5.2 It is currently unknown to the Parties whether the updated
Facets-ClaimCheck Interface provided for in Section 5.1 above will also function as an interface between Facets and ClaimsXten. In the event the updated Facets-ClaimCheck Interface is not functional as an interface between Facets and
ClaimsXten, TriZetto will build, on a cost basis at McKesson’s expense, a new interface between Facets and ClaimsXten, provided that the Facets- 

  

 17 

 
ClaimsXten Interface need only contain similar functionality to the Facets-ClaimCheck Interface. For purposes of this Section 5.2, TriZetto’s costs
payable by McKesson shall include TriZetto’s actual payroll costs and out of pocket costs and fees, but shall not include any general administrative and overhead costs. 
 5.3 Except as expressly provided herein, TriZetto shall not be obligated to build any other interfaces for any of the Parties’ prior,
existing, or future products. 
 5.4 McKesson acknowledges that TriZetto may create interfaces between Facets and other
third-party Clinical Editing Products. As a result of this Agreement, TriZetto will distribute at least two versions of Facets products, one with a Clinical Editing Product and one without a Clinical Editing Product. TriZetto will create interfaces
between both versions of Facets and ClaimCheck and, if applicable, ClaimsXten. TriZetto shall have the right to create interfaces between both such versions of Facets and third party Clinical Editing Products. If, in the future, TriZetto upgrades
either such version of Facets such that new or updated interfaces to ClaimCheck and, if applicable, ClaimsXten are necessary, TriZetto shall release a general availability version of such new or updated interfaces between Facets and ClaimCheck and,
if applicable, ClaimsXten no later than TriZetto releases a general availability version of the interface(s) between Facets and any third party Clinical Editing Product. 
 5.5 During the Term, McKesson will provide TriZetto with application, technical, and administrative training and support for all
interfaces and for McKesson Products at no additional cost to TriZetto, and TriZetto will provide McKesson with application, technical, and administrative training and support for all interfaces at no additional cost to McKesson. 
 5.6 TriZetto will work in good faith with McKesson to create and distribute press releases announcing enhanced releases and upgrades of
the Facets-ClaimCheck Interface. 
  

 18 

 5.7 As to those interfaces set forth in Sections 5.1 and 5.2 (if applicable) above,
TriZetto will provide, directly to the customer, first-level support for the interface(s), and will develop, support, and provide upgrades to those interfaces in accordance with this Agreement and TriZetto’s standard Facets maintenance and
release schedule, provided that TriZetto supports the two most current versions of the interface software. TriZetto agrees that it will develop and maintain the updated Facets-ClaimCheck Interface described in Section 5.1 above according to the
specifications that are requested by McKesson and/or a customer, and accepted by TriZetto, provided, however, that such acceptance shall not be unreasonably withheld. TriZetto will provide and support the interface(s) described in Section 5.1
and (if applicable) Section 5.2 to New Facets and ClaimFacts Customers for no additional charge to McKesson or the customer. TriZetto may charge Existing TriZetto Customers reasonable fees to license, support and maintain the interface(s).

 5.8 McKesson will provide directly to all Facets customers using the Facets-ClaimCheck Interface and (if applicable) the
Facets-ClaimsXten Interface all McKesson Products product support and back-up support for the interface(s) described in Section 5.1 and (if applicable) Section 5.2. 
 5.9 Each Party will retain any and all revenue generated from their provision of consulting, implementation, and training services.

 5.10 TriZetto will provide McKesson written notice (email is acceptable) of delivery of the Facets-ClaimCheck Interface and
(if applicable) the Facets-ClaimsXten Interface to each New and Existing Facets Customer promptly after deliver to said customer. 
  

 19 

	 	6.	The Litigation. 

 6.1 Within
five (5) business days following the Effective Date of this Agreement, McKesson will file with the Court a dismissal with prejudice of the Action, including all claims and counterclaims asserted therein, to be signed by both Parties. Neither
Party shall pursue appeal of any aspect of the Action. Each Party shall bear its own costs and fees, including its own attorneys’ fees. 
 6.2 McKesson, on behalf of itself and its counsel, agrees to cooperate with TriZetto (including without limitation executing an appropriate stipulation) in requesting that the Court maintain under seal certain
admitted trial exhibits that contain technical information, product manuals, and product descriptions of the TriZetto products. 
 6.3 Within ten (10) business days of the filing of the dismissal as set forth in Section 6.1, all copies of each Party’s software and/or source code produced in the Action, including all notes and copies thereof, shall be
permanently erased from any computers or networks maintained by the other Party, its counsel, and/or its consultants. Furthermore, any copies of such software or source code maintained on removable media (or produced by the Parties) shall be
returned to the producing Party within such period. All remaining materials produced or created in accordance with the Stipulated Protective Order entered in the Action shall be treated in accordance with Sections 14.2 and 14.3 of that Order.

  

	 	7.	Representations and Releases 

 7.1 The Parties hereby represent and warrant to each other that they have not sold, transferred, assigned, hypothecated, or otherwise encumbered any claim, cause of action, defense, or right alleged in the Pleadings and Filings or the
Action. 
  

 20 

 7.2 Each Party represents and warrants to the other that it has the authority to enter
into and execute this Agreement and bind its respective corporate entity to the terms and conditions set forth in this Agreement. 
 7.3 Each Party represents and warrants to the other that entering into this Agreement and performing such Party’s obligations hereunder will not violate or result in a breach or default under any agreement to which such Party or its
assets are bound. Each Party shall indemnify and hold harmless the other from any claim that such a violation or breach has resulted from the execution and or performance of this Agreement. 
 7.4 The Parties represent and warrant to each other that no lawsuit(s) other than the Action have been commenced or filed in any forum
arising out of or in connection with any of the claims alleged or defenses asserted in the Pleadings and Filings, the Action or this Agreement. 
 7.5 The Parties represent and warrant to each other that each is a corporation duly incorporated, validly existing and in good standing under the laws of the state of its incorporation as set forth in the first
paragraph of this Agreement, with full corporate power and authority to carry on its business as it is now being conducted. 
 7.6 The Parties represent and warrant to each other that the execution, delivery and performance by each of this Agreement, and the consummation by each of the transactions contemplated hereby, have been duly authorized and no other
corporate action is necessary to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. 
  

 21 

 7.7 The Parties represent and warrant to each other that each has not entered and
covenant that each will not enter into any agreement, the execution and/or performance of which will violate any term of this Agreement. 
 7.8 The Parties represent and warrant to each other that all of the approvals, authorizations, permits, licenses, waivers and consents required or filings to be made or notices required to be given by each Party that
are necessary to accomplish the transactions contemplated by this Agreement have been duly obtained or made by such Party. 
 7.9 Each person who executes this Agreement on behalf of each Party represents and warrants to the other Party that he or she has the authority of the respective directors and officers of the Party to do so, and each Party agrees to
indemnify and hold harmless the other Party from any claim that such authority did not exist. 
 7.10 The Parties represent
and warrant to each other: 
 (a) That each has conferred with its own legal counsel for purposes of executing this Agreement;

 (b) That each understands the legal nature and effect of this Agreement; 
 (c) That each has carefully read this Agreement and knows the contents thereof and that each signs the same freely and voluntarily;

 (d) That each has not relied upon the advice of an adverse party’s counsel in executing this Agreement; 
 (e) That each has not relied upon any representation or statement of an adverse party in executing this Agreement except as set forth
herein; and 
 (f) That each is aware that facts may hereafter be discovered that are different from or in addition to the
facts that each now knows or believes to be true with respect 

  

 22 

 
to the subject matter of the Action, the issues raised in the Pleadings and Filings, the ‘164 patent, or this Agreement, but it is each Party’s
intention to fully and finally release each other as hereinafter set forth. Accordingly, McKesson and TriZetto understand the significance of and, as further consideration for this Agreement, expressly waive any right or benefit that may be
available under Section 1542 of the California Civil Code or any similar laws. Section 1542 of the California Civil Code provides: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR.

 7.11 McKesson for itself, and for its respective officers, directors, shareholders, joint venturers, partners,
insurers, attorneys, employees, independent contractors, agents, representatives, predecessors (including HPR, HBOC and GMIS), successors and assigns, and for any parent, subsidiary or affiliate corporation, alter ego, partnership, or other related
person or entity, and each of their respective officers, directors, shareholders, joint venturers, partners, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors, successors and assigns, do hereby release,
acquit, and forever discharge TriZetto, its past, present and future customers, officers, directors, shareholders, joint venturers, partners, customers, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors
(including Erisco and RIMS), successors, assigns, parent, subsidiary and other affiliated entities, alter ego, partnership, or other related person or entity, and each of their respective officers, directors, shareholders, joint venturers, partners,
insurers, attorneys, employees, independent contractors, agents, representatives, predecessors, successors and assigns, from any and all claims, actions, causes of action, demands, rights, damages, liabilities, losses and costs of any 

  

 23 

 
kind and nature whatsoever, either known or unknown, suspected or unsuspected, liquidated or contingent, arising, accruing or occurring at any time up to and
including the Effective Date of this Agreement which the Party made or could have made in the Action. 
 7.12 During the Term
of this Agreement, McKesson covenants not to sue or threaten to sue TriZetto or any TriZetto employee, representative, or agent for alleged infringement of the ‘164 Patent or any other patent applied for by or issued or assigned to McKesson as
of the Effective Date of this Agreement based on TriZetto making, using or selling any Covered Product or TriZetto Clinical Editing Product. This covenant not to sue shall not preclude McKesson from seeking its available remedies and relief for
TriZetto’s breach of this Agreement, including, without limitation and as applicable, liquidated damages and injunctive relief as set forth in Sections 11.7 and 11.8, respectively. In the event that this Agreement is assigned or otherwise
transferred by TriZetto to a third party, this covenant not to sue shall not preclude McKesson from suing the assignee or transferee for infringement of the ‘164 Patent based on products other than products that TriZetto was offering prior to
the assignment or transfer. This covenant not to sue shall also apply to any claim by McKesson against any TriZetto customer licensed under this Agreement for alleged infringement of the ‘164 Patent based on the customer’s purchase or use
of the TriZetto product(s) that the customer is licensed to use under this Agreement. During the Term of this Agreement, TriZetto covenants not to sue or threaten to sue McKesson Corporation or any McKesson employee, representative or agent for
alleged infringement of any patent applied for by or issued or assigned to TriZetto as of the Effective Date of this Agreement based on McKesson making, using or selling a McKesson Clinical Editing Product. 
  

 24 

 7.13 TriZetto for itself, and for its respective officers, directors, shareholders, joint
venturers, partners, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors (including Erisco and RIMS), successors and assigns, and for any parent, subsidiary or affiliate corporation, alter ego, partnership,
or other related person or entity, and each of their respective officers, directors, shareholders, joint venturers, partners, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors, successors and assigns, do
hereby release, acquit, and forever discharge McKesson, its past, present and future officers, directors, shareholders, joint venturers, partners, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors
(including HPR, HBOC and GMIS), successors, assigns, parent, subsidiary and other affiliated entities, alter ego, partnership, or other related person or entity, and each of their respective officers, directors, shareholders, joint venturers,
partners, insurers, attorneys, employees, independent contractors, agents, representatives, predecessors, successors and assigns, from any and all claims, actions, causes of action, demands, rights, damages, liabilities, losses and costs of any kind
and nature whatsoever, either known or unknown, suspected or unsuspected, liquidated or contingent, arising, accruing or occurring at any time up to and including the Effective Date of this Agreement which the Party made or could have made in the
Action. 
 7.14 During the Term of this Agreement, TriZetto covenants and agrees not to seek in any proceeding (including
without limitation a proceeding to enforce this Agreement) or assist any third party (except as may be compelled by compulsory process or court order) to have the ‘164 Patent or any claim thereof declared, determined or adjudicated invalid or
unenforceable. As used herein, “proceeding” shall be interpreted broadly and includes, without 

  

 25 

 
limitation, any and all court or administrative proceedings and/or a reexamination proceeding in the United States Patent and Trademark Office. 

 

	 	8.	Confidentiality 

 8.1 The
Parties agree to keep the terms of this Agreement (including exhibits) confidential and further agree not to disclose them to any other person who is not a signatory to this Agreement or without the prior written consent of the other Party, except
to the following persons, entities, or instances: 
 (a) to the directors or officers of a Party or its affiliate(s);

 (b) as deemed reasonably necessary or appropriate by a Party to its accountants, auditors, and/or legal counsel in
connection with the advice and/or services offered by such entities; 
 (c) pursuant to an appropriate non-disclosure
agreement containing confidentiality provisions consistent with Section 8 of this Agreement in connection with the sale of the Party or the business related to this Agreement; 
 (d) to shareholders, markets, and/or regulatory bodies as may be required or deemed advisable pursuant to applicable law or regulation
(including, but not limited to, any Federal or state securities law or SEC regulation), or pursuant to any agreement with an applicable stock exchange or quotation service; 
 (e) to any person or entity as may be required by the order of a court of competent jurisdiction; 
 (f) in connection with proceedings to enforcement of the terms of this Agreement; or 
  

 26 

 (g) to any Party employee who is required to have such information in connection with the
performance of the provisions set forth in Sections 3, 4 or 5 of this Agreement, provided that disclosure to such Party employee is limited to Sections 3, 4 and 5 of this Agreement. 
 In connection with any disclosures permitted under this Section 8, the disclosing Party shall make reasonable efforts to only
disclose as much of the Agreement as reasonably prudent or required, and, if appropriate, seek appropriate confidentiality in connection with such disclosures. By way of example only, if a disclosure is required under paragraphs (e) or
(f) above, the disclosing Party shall make reasonable efforts to make such disclosure pursuant to an appropriate confidentiality order. Additionally, the Parties agree that McKesson shall take all reasonable efforts to further avoid the
disclosure of the contents of Exhibit 1 and 2 to any person that may use such information for competitive business purposes other than for purposes of promoting, marketing, or selling McKesson Products to New and Existing Facets Customers.
Notwithstanding the foregoing, the Parties agree that subject to any terms of the Communications Plan (described in Section 8.3) relating to the timing of disclosures, each Party may disclose to any person without the prior written consent of
the other Party the fact that the Parties have settled the Action on confidential terms. 
 8.2 Each Party has disclosed, and
may in the future disclose, to the other certain confidential and proprietary technical or business information or materials which (a) if disclosed in writing, are designated as confidential in writing by the disclosing Party, whether by letter
or by the use of an appropriate stamp or legend, prior to or at the time any such know-how or other information or material is disclosed by the disclosing Party to the other Party, or (b) if disclosed orally or visually, are identified as
confidential at the time of disclosure, and later 

  

 27 

 
described in a writing complying with section (a) above (hereinafter “Confidential Information”). The Parties acknowledge that the
Confidential Information is competitively sensitive and commercially valuable, the design and development of which involve the expenditure of substantial amounts of money and the use of skilled development personnel over a long period of time. Each
Party agrees that it will not use any Confidential Information received from the other Party except for the purposes of this Agreement. Absent prior written consent of the other Party, each Party will not disclose such Confidential Information to
any person other than those of the Party’s employees who are required to have such information to perform the obligations set forth in this Agreement. TriZetto further agrees that absent prior written consent of McKesson, TriZetto will not
disclose any of McKesson’s Confidential Information to any non-TriZetto employee who participates in any way in making, developing, revising, updating, supporting, maintaining, marketing or selling any non-TriZetto Clinical Editing Product
(other than a McKesson Product). Absent prior written consent of McKesson, any non-TriZetto employee to whom TriZetto has disclosed McKesson’s Confidential Information shall not participate in any way in making, developing, revising, updating,
supporting, maintaining, marketing or selling any non-TriZetto Clinical Editing Product (other than a McKesson Product) during the Term of this Agreement. Each Party agrees to maintain and follow reasonable procedures to prevent unauthorized
disclosure or use of Confidential Information received from the other Party. Each Party shall immediately advise the other Party of any discovered disclosure, loss or use of that other Party’s Confidential Information in violation of this
Agreement. The restrictions set forth in this Section 8.2 shall not apply to information (a) available to the public other than by a breach of this Agreement or any other obligation of confidentiality; (b) rightfully received from a
third party not in breach of any obligation of confidentiality; or (c) that a Party is ordered to produce 

  

 28 

 
by subpoena or other judicial or governmental order, or the rules of a stock exchange or the NASD, provided that said Party shall immediately notify the
other Party in writing and provide the other Party a copy of the subpoena, order or rule, and shall provide no less than ten (10) business days notice of the proposed release of such information; each Party shall take appropriate measures to
avoid or minimize the release of such information in connection with the proceedings for which the information is sought. 
 8.3 Consistent with and notwithstanding the provisions of this Section 8, upon the Effective Date of this Agreement, the Parties will agree on an internal and external communications plan (the “Communications Plan”) regarding
this Agreement. Other than communications expressly allowed by the Communications Plan, disclosure of the terms of this Agreement and/or any comment or opinion whatsoever regarding the same shall be governed by Sections 8.1 and 8.2 above,
provided, however, that the contents of any public announcement, press release or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party in any form without a requirement for
re-approval, but only if (a) such re-release does not, by omission, materially change the meaning of such previously approved public announcement, press release or similar publicity; and (b) (i) the circumstances affecting the matters
in such previously approved public announcement, press release or similar publicity, and (ii) the commercial or contractual relationship between the Parties, in each case has not changed in any material respect. 
  

	 	9.	Termination 

 9.1 Except for
(1) Sections 7, 8, 10 and 11 and (2) obligations that come into existence during the term of this Agreement regarding (i) the Parties’ support obligations to existing customers utilizing the interface(s) developed pursuant to
Section 5 of this Agreement 

  

 29 

 
and (ii) the Parties’ payment obligations, this Agreement shall terminate upon the expiration of the Term, unless modified by mutual written
agreement of the Parties. Except for the provisions expressly noted in the preceding sentence and unless otherwise extended by mutual agreement of the Parties, termination of this Agreement shall release any Party hereto from any future obligation
that would be due under the terms of this Agreement. 
  

	 	10.	Notice 

 Any notice or other
communication to be made pursuant to this Agreement shall be sent to the other Party at its address listed below or at such other address such Party may hereinafter designate to the other Party in writing: 
 If to McKesson: 
 Senior Vice
President and General Manager 
 Clinical Auditing and Compliance Division 
 McKesson Health Solutions 
 5 County View
Road 
 Malvern, Pennsylvania 19355 
 With a copy to: General Counsel 
 If to TriZetto: 
 Chief Executive Officer 
 The TriZetto
Group, Inc. 
 567 San Nicolas Drive, Suite 360 
 Newport Beach, California 92660 
 With a copy to: General Counsel 
 Notice shall be deemed to have been given: (i) at the expiration of two (2) business days from the business day of the date of
delivery by facsimile transmission, provided a copy is deposited postage prepaid for delivery with the postal service or given for delivery to a nationally-recognized express courier service on the same date as the sending of the facsimile and the
facsimile is delivered during regular business hours, (ii) seven (7) business days from the 

  

 30 

 
date the communication is deposited postage prepaid with the postal service or given to a nationally-recognized express courier service, unless actual
receipt of the notice at an earlier date is established, or (iii) at the expiration of one (1) business day of the business day delivered, if delivered by hand and during regular business hours. Without limitation of the foregoing, a
written receipt signed by the addressee or its duly appointed representative situated at the addresses set forth hereinabove shall constitute sufficient evidence of service. Either Party may change its address and facsimile information by written
notice given in accordance with the provisions of this Section 10. 
  

	 	11.	Miscellaneous 

 11.1 The
Parties hereto agree to bear their own costs, expenses and attorneys’ fees. Each Party shall bear its own tax liability in connection with the receipt of any payments made pursuant to this Agreement. 
 11.2 This Agreement shall be governed by the laws of the State of California without reference to its conflict of laws principles and, to
the extent applicable, United States federal law governing patents. 
 11.3 This Agreement may be executed in counterparts,
each of which shall be deemed a duplicate original, but all of which together shall constitute one and the same instrument. For purposes hereof, a facsimile copy of this Agreement, including the signature pages hereto, shall be deemed an original.

 11.4 This Agreement shall be binding upon, and inure to the benefit of, the Parties hereto and their respective
administrators, attorneys, representatives, and those successors and assigns permitted under Section 2.3(b) above. 
  

 31 

 11.5 In the event of an alleged breach of this Agreement, the non-breaching Party may
terminate this Agreement if (i) said Party provides written notice to the breaching Party in accordance with Section 10 of this Agreement specifying in reasonable detail the alleged breach; and (ii) within thirty (30) days from
the date of such notice, the breaching Party fails to cure such breach, demonstrate the nonexistence of such breach, or take reasonable good faith steps towards curing such breach. 
 11.6 If this Agreement is terminated for any reason prior to the expiration of the Term, TriZetto shall cease all sales, offers for sale,
licenses or other transfers of TriZetto Clinical Editing Products (whether alone or as part of another product) and, if said termination occurs before all of the payments herein provided for have been made, TriZetto shall within thirty
(30) days pay to McKesson any remaining unpaid balance even if the due date for such payment has not been reached; provided, however, that (i) TriZetto’s then-existing customers (and any applicable successors) licensed under this
Agreement may continue to use the TriZetto products (including permitted upgrades or new versions of such products) to the same extent that they were permitted to use such products prior to the date of such termination; and (ii) except in the
event McKesson terminates this Agreement pursuant to Section 2.3(b), TriZetto may continue to use, support, host, maintain, update and/or upgrade such products for such then-existing customers licensed under this Agreement to the same extent it
was permitted to do so prior to the date of such termination. If this Agreement is terminated before October 12, 2010, TriZetto also shall continue to perform the maintenance, support and upgrade obligations set forth in Section 5 of this
Agreement for its then-existing customers using the Facets-ClaimCheck Interface or, if applicable, the Facets-ClaimsXten Interface to the same extent it was required to do so prior to the date of such termination through October 12, 2010.

  

 32 

 11.7 In the event that TriZetto commits a material breach of this Agreement and TriZetto
has not cured or taken reasonable good faith steps to cure such breach within the time set forth in Section 11.5, McKesson shall be entitled to recover through the dispute resolution provisions of this Agreement, and upon proof of a material
breach, liquidated damages in the amount of one million dollars ($1,000,000); provided that the foregoing amount of liquidated damages is not a penalty and damages for the breach are impossible to reasonably estimate. 
 11.8 Following the efforts of the Parties to amicably resolve such dispute in accordance with Section 11.10 of this Agreement, in
addition to the rights and remedies available to McKesson under this Agreement and by law, in the event that (i) there is a material breach of this Agreement, and (ii) TriZetto does not cure or take reasonable good faith steps to cure such
breach within the time set forth in Section 11.5, McKesson may apply to a Court of competent jurisdiction (including the District of Delaware) for preliminary injunctive or other equitable relief against TriZetto during the pendency of the
arbitration proceedings in accordance with the provisions of Section 11.10 of this Agreement. Notwithstanding the foregoing, TriZetto may oppose any request for such preliminary or equitable relief sought by McKesson on any applicable grounds.
In addition, in the event of a final, non-appealable determination that TriZetto has committed a material breach of Section 2.4 of the Agreement, and so long as McKesson does not terminate this Agreement, TriZetto agrees that McKesson shall be
entitled to an injunction or other equitable relief prohibiting such breach by TriZetto. However, in no event shall TriZetto be prohibited from offering the Clinical Editing Products beyond the Term. 
  

 33 

 11.9 No breach of any provision hereof can be waived unless in writing. Waiver of any one
breach shall not be deemed to be a waiver of any other breach of the same or any other provision hereof. 
 11.10 The Parties
agree to use their best efforts to handle all disputes, claims or controversies arising under, out of, or in connection with this Agreement in good faith and in an expeditious and cost-effective manner. The Parties shall first attempt to resolve any
dispute amicably between themselves by arranging an in-person meeting between executives with decision-making authority within thirty (30) days of a request by either Party for such a meeting. If the Parties fail to resolve such dispute within
said thirty-day period, then the dispute shall be decided through binding arbitration conducted by a retired federal judge affiliated with JAMS in California, the identity of such arbitrator to be mutually agreed upon by the Parties. If mutual
agreement cannot be reached as to who shall serve as the arbitrator, the Parties agree that JAMS shall designate the neutral arbitrator possessing the foregoing credentials and who is sufficiently familiar with patent disputes to render a complete
decision in the matter. The arbitrator shall issue a written decision following such arbitration, setting forth in sufficient detail all reasons and bases for his or her decision. In the event of any alleged breach of Sections 3, 4, 5 or 8 of this
Agreement, the Parties agree that the arbitration shall be conducted on an expedited basis and must be concluded within 60 days of the initiation of the arbitration. The provisions of this section may be enforced by any court of competent
jurisdiction. The prevailing Party in the arbitration or a proceeding to enforce this arbitration provision shall be entitled to an award of all costs, fees and expenses, including attorneys’ and expert fees, incurred in such arbitration or
enforcement proceeding, respectively, to be paid by the Party against whom the arbitration or enforcement proceeding is decided. The submission of disputes to arbitration as provided for in 

  

 34 

 
this Section 11.10 does not apply to requests for the equitable remedies afforded to McKesson in Section 11.8. 
 11.11 This is an integrated Agreement. All agreements, covenants, representations and warranties, express or implied, oral and written, of
the signatories concerning the subject matter hereof are contained herein. No other agreements, covenants, representations, or warranties, express or implied, oral or written, have been made by any Party hereto to any adverse party concerning the
subject matter hereof. All prior and contemporaneous conversations, negotiations, possible and alleged agreements, representations, covenants, and warranties concerning the subject matter hereof, including without limitation the term sheet(s)
exchanged by the Parties, are merged herein and shall be of no further force or effect. This Agreement and the covenants herein may not be altered or amended except by a writing executed by the Parties. 
 11.12 Paragraph titles or captions contained in this Agreement are used for convenience or reference only, and are not intended to and
shall not be construed in any way to enlarge, define, limit, extend, or describe the rights or obligations of the signatories or affect the meaning or construction of this Agreement or of any provision hereof. 
 11.13 Each Party to this Agreement acknowledges that it has been represented by independent counsel in connection with the negotiation of
this Agreement and which counsel has participated in the drafting of this Agreement. Neither this Agreement nor specific language contained herein shall be construed against the Party preparing it, but shall be construed as if both Parties, and each
of them, jointly prepared it, and any uncertainty or ambiguity shall not be interpreted against any one Party. 
  

 35 

 11.14 TriZetto’s customers who are licensed, subject to the covenant not to sue,
and/or released as set forth in this Agreement shall be expressly deemed to be third party beneficiaries of the applicable provisions of this Agreement. 
 11.15 TriZetto and McKesson are independent contractors and the relationship established under this Agreement shall not be construed as a partnership, joint venture or other form of joint enterprise, nor shall one
Party be considered the agent of the other. Neither Party is authorized to make any representations or create any obligations or liability on behalf of the other Party, except as may be expressly provided for in this Agreement. 
 11.16 Any provision of this Agreement that is held unenforceable or invalid for any reason by a court of competent jurisdiction shall be
severed from this Agreement, and the remainder of the Agreement shall continue in effect; provided, that such unenforceable or invalid provision shall be given effect to the maximum extent then permitted by law. 
 IN WITNESS WHEREOF, McKesson and TriZetto have executed this Agreement as of the last date below. 
 DATED: September 7, 2006 
  

			
	MCKESSON INFORMATION SOLUTIONS LLC
		
	By:	 	/s/ Laureen E. Seeger
	Name:	 	Laureen E. Seeger
	Its:	 	Vice President and Secretary

  

 36 

 DATED: September 7, 2006 
  

			
	THE TRIZETTO GROUP, INC.
		
	By:	 	/s/ James J. Sullivan
	Name:	 	James J. Sullivan
	Its:	 	Senior Vice President, General Counsel

  

 37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]